Ergebnisse für *

Zeige Ergebnisse 1 bis 6 von 6.

  1. Non-violation and situation complaints under the TRIPS Agreement
    implications for developing countries
  2. Guide for the granting of compulsory licenses and government use of pharmaceutical patents
    Erschienen: 2020
    Verlag:  South Centre, Geneva

    Zugang:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)
    Universitätsbibliothek Braunschweig
    keine Fernleihe
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    DS 751
    keine Fernleihe
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
  3. Guía para la concesión de licencias obligatorias y uso gubernamental de patentes farmacéuticas
    Erschienen: 2020
    Verlag:  South Centre, Ginebra

    Zugang:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    DS 751
    keine Fernleihe
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
    Quelle: Verbundkataloge
    Sprache: Spanisch
    Medientyp: Buch (Monographie)
    Format: Online
    Weitere Identifier:
    hdl: 10419/232228
    Schriftenreihe: Documento de investigación / South Centre ; 107 (Diciembre de 2020)
    Schlagworte: Access to Medicines; Affordable Medicines; Compulsory Licenses; COVID-19; Data Exclusivity; Diagnostics; Doha Declaration on the TRIPS Agreement and Public Health; Evergreening; Flexibilities; Global Health; Government Use; Health; Innovation; Intellectual Property; Least Developed Countries (LDCs); Patent; Pharmaceuticals; Public Health; Research and Development (R&D); TRIPS; Vaccines; Voluntary License; WHO; WHO Global Strategy (GSPOA); World Health Organization (WHO)
    Umfang: 1 Online-Ressource (circa 44 Seiten), Illustrationen
  4. The comprehensive and progressive agreement for the trans-pacific partnership
    data exclusivity and access to biologics
    Erschienen: 2020
    Verlag:  South Centre, Geneva

    Zugang:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    DS 751
    keine Fernleihe
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
  5. Revisiting the question of extending the limits of protection of pharmaceutical patents and data outside the EU
    the need to rebalance
    Erschienen: 2020
    Verlag:  South Centre, Geneva

    Zugang:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)
    Universitätsbibliothek Braunschweig
    keine Fernleihe
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    keine Fernleihe
    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
    Quelle: Verbundkataloge
    Sprache: Englisch
    Medientyp: Buch (Monographie)
    Format: Online
    Weitere Identifier:
    hdl: 10419/232253
    Schriftenreihe: Research paper / South Centre ; 127 (December 2020)
    Schlagworte: Access to Medicines; Biologics; Bolar; Data Exclusivity; European Union (EU); Flexibilities; Free Trade Agreements (FTAs); Generic Medicines; Health; India; Innovation; Intellectual Property; Intellectual Property (IP) Enforcement; Patent; Patent Term; Pharmaceuticals; TRIPS
    Umfang: 1 Online-Ressource (circa 52 Seiten)
  6. Negotiating health and autonomy
    data exclusivity, healthcare policies and access to pharmaceutical innovations

    This paper analyzes the debate over the international dissemination of data exclusivity as a form of protection for clinical trial data. This is a critical demand for pharmaceutical companies seeking larger market shares and longer periods of... mehr

    Zugang:
    Verlag (kostenfrei)
    Verlag (kostenfrei)
    Resolving-System (kostenfrei)
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    DS 751
    keine Fernleihe

     

    This paper analyzes the debate over the international dissemination of data exclusivity as a form of protection for clinical trial data. This is a critical demand for pharmaceutical companies seeking larger market shares and longer periods of monopoly in order to recover investments in research and development and greater profitability. However, this is a sensitive issue with economic and social repercussions for developing countries that adopt this protection regime. This paper highlights critical issues for the political economy of innovation and presents a review of empirical studies that show that data exclusivity delays the entry of generic drugs into the market, increasing prices and reducing access. At the same time, its adoption has no benefits because there are no positive effects on internal technological innovation, nor reduction of the "International drug lag", nor the development of drugs for specific epidemiological demands.

     

    Export in Literaturverwaltung   RIS-Format
      BibTeX-Format
    Quelle: Verbundkataloge
    Sprache: Englisch
    Medientyp: Buch (Monographie)
    Format: Online
    Weitere Identifier:
    hdl: 10419/301244
    Schriftenreihe: Research paper / South Centre ; 204 (24 July 2024)
    Schlagworte: Access to Medicines; Clinical Trials; Data Exclusivity; Generic Medicines; Health; Healthcare; Innovation; Intellectual Property; Pharmaceuticals; Research and Development (R&D); Test Data; Test Data Protection; TRIPS; TRIPS Agreement
    Umfang: 1 Online-Ressource (circa 34 Seiten)